PCSC headed into today's earnings release carrying a week of diverging signals — a short score that peaked near 76 mid-week before pulling back, a stock quietly grinding higher, and a Q1 print that landed with zero EPS versus $0.06 a year ago.
The most notable shift this week was in short positioning sentiment. The ORTEX short score hit 75.7 on May 8 — its highest reading of the past two weeks — before easing to 69.3 by May 12. That's still firmly elevated, and a score in the upper 60s reflects meaningful bearish conviction relative to the broader universe. Absolute short interest held in a tight range of roughly 732,000 to 780,000 shares across the past 30 days, with the latest reading near 759,600. Against a free float, that translates to 41.3% of shares — a high level that signals a substantial number of investors are positioned against the name.
The borrow market tells a different story from the headline short score. Availability is extremely loose at roughly 1,352% of short interest — meaning the pool of shares available to borrow is more than 13 times the current short position. That points to no meaningful squeeze pressure in the lending market. Cost to borrow is running at 4.6%, a touch below its 30-day average after peaking near 7.1% in mid-April. The pullback in CTB from those April highs aligns with the easing availability trend — borrowing PCSC is relatively uncomplicated right now, despite the large short position.
The ownership structure is worth noting. Farallon Capital Management entered a full 2.25 million share position as of December 2025, becoming the second-largest holder behind the sponsor entity at 21.3%. Several other specialist funds — RA Capital, RTW Investments, BIT Capital, Holocene Advisors, One Fin Capital — built new positions around the same period, with Aberdeen Group adding 232,000 shares as recently as April 1. The register reads like a who's-who of SPAC-arbitrage and healthcare-focused investors, most of whom entered or added within the past six months. With 43 institutional holders collectively owning a significant chunk of the float, the stock's relative calm despite heavy short interest likely reflects locked-up or arbitrage-oriented positioning on both sides.
Earnings reactions here have been modest. The last four events produced moves of -0.18%, -1.68%, 0.0%, and -0.20% on the day, all in a tight band. Five-day reactions were similarly subdued, peaking at -2.8%. Today's Q1 release — EPS of $0.00, down from $0.06 a year prior — fits the pattern of a company in pre-deal SPAC mode, where the P&L is largely uninformative and investors are watching for deal announcements rather than operating metrics. The stock added 0.44% on the week heading into the print, having gained about 3.1% over the past month to trade near $11.30.
The next development worth watching is whether the owner-concentration dynamic shifts ahead of any target announcement — specifically whether the new institutional entrants hold or trim as the deal timeline becomes clearer.
See the live data behind this article on ORTEX.
Open PCSC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
